Corcept Therapeutics Inc (CORT) income statement
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30537% above fair value
$67.79−2.28 (-3.25%)
Close on Nov 18, 2026Market cap $7.33BP/E 161.4Yield –
Corcept Therapeutics Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 98.3%
- Operating margin
- 0.8%
- Net margin
- 6.6%
- Return on equity, FY2025
- 15.0%
Financial strength
- Current ratio
- 2.86
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 72.2%
Valuation
- P/E ratio
- 161.4
- Price to sales
- 8.82
- Price to book
- 10.38
- Dividend yield
- –
See a number that looks wrong?